Compare Fox Corp Class B (FOX) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs IDEXX Laboratories, Inc. — how do they compare? Fox Corp Class B trades at $55.89 (market cap $25.36B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Fox Corp Class B pays a 1.02% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| FOX | IDXX | |
|---|---|---|
Market Cap | $25.36B | $40.43B |
Volume | 886,620 | 692,164 |
Sector | Media | Health |
52-Week High | $67.76 | $766.68 |
52-Week Low | $44.39 | $504.70 |
Typical Hold Time | 75 Days | 46 Days |
Enterprise Value | $28.72B | $41.32B |
Dividend Yield | 1.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $56.97, up 1.77% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $16.30B in 2025, with net income reaching $2.26B and a profit margin of 13.88%. The stock is supported by positive analyst sentiment, with a consensus price target of $84.75, indicating significant upside potential from current levels.
The outlook for FOX is favorable, driven by robust profitability and valuation metrics below industry averages. Key risks include a projected decline in 2026 net income and ongoing regulatory scrutiny of acquisitions. The stock presents a compelling opportunity for value-oriented investors, though monitoring execution on future earnings is critical.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
